Bioton enters the haematogenous drugs market

The company signed a leasing contract with the receiver of a bankrupt blood plasma laboratory in Mielec. Bioton will lease the plant for 10 years with pre-emption rights. The rent will be zl.80,000 per month. Bioton also signed a contract with one of the leading Europeans producers of haematogenous products. This will enable Bioton to complete the investment and introduce new technologies. Another insulin producer, Polfa Tarchomin, is likely to gain 5% share of the market as its products have been put on the list of refunded medicines. The success of Bioton was mainly caused by the fact that its products were refunded. But according to analysts, Polfa Tarchomin will not threaten Bioton's position. (Rzeczpospolita, January 6-7, p. B3) M.M.